Send us Fan Mail

How will Most Favored Nation (MFN) pricing reshape global pharmaceutical strategy? What do emerging Centers for Medicare & Medicaid Service (CMS) models such as GENEROUS, GLOBE, and GUARD mean for launch planning, pricing corridors, and payer expectations worldwide? How should global market access teams prepare for a more transparent and tightly connected pricing environment?

MFN reform is already influencing how companies plan, price, and launch medicines around the world. While CMS proposals sit at the center of the debate, the implications extend far beyond the US. The increased transparency required in models under consideration has the potential to accelerate global price convergence, affect international reference dynamics, and place new pressures on evidence generation, launch sequencing, and global pricing corridors.

This episode was first broadcast as a live webinar on Wednesday 15th April 2026. It is designed to help global and US teams understand and anticipate the worldwide strategic implications of MFN policy.

The session brought together four experts offering global and US perspectives on MFN:

• Steve O’Malley (President, Petauri Advisors): Moderator and contributor on US access and strategic implications
• Catherine Beecher (Director – Global Pricing and Market Access, Petauri Evidence): Bringing insight into global evidence requirements, lifecycle planning, and cross‑market pricing pressures
• Clare Foy (Director – Global Pricing and Market Access, Petauri Evidence): Bringing expertise in global pricing strategy and launch planning across international markets
• Michael Garner (Vice President, Artia Solutions – Powered by Petauri): Bringing US Medicaid expertise with a focus on CMS MFN proposals and their operational and strategic implications

Learn more at: https://petauri.com/insights/global-market-access-strategy-for-mfn/

In this webinar, we explored:

• The most recent CMS MFN policy developments and how models such as GENEROUS, GLOBE, and GUARD may evolve
• The possible effects of the recent announcement of new tariffs on pharmaceutical manufacturers
• How greater price transparency could affect international pricing corridors and global revenue forecasts
• Impacts on launched products, peri-launch assets, and early pipeline programs from both a global and US policy standpoint
• Strategic options for optimizing ex-US price potential, including evidence generation, innovative agreements, conditional reimbursement, and launch sequencing
• How global market access teams can build pricing and access strategies that remain resilient as MFN models evolve
• Wider policy developments to monitor outside the US, including proposed changes to the exclusivity period in the EU, and the growing influence of the Joint Clinical Assessment

Learn more about our pricing and market access strategy services.

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Send us Fan Mail

How do LATAM healthcare markets differ and what do these differences mean for Pharma and Medtech launch planning? What should global market access teams know to support affiliates in Argentina, Brazil, Colombia, and Mexico? How do evidence requirements, access routes, and payer expectations vary across the region?

For global market access teams planning for launch in Latin America (LATAM), understanding the diversity and complexity of this region is essential. Healthcare systems vary significantly between markets, regulatory and payer expectations differ, and health technology assessment (HTA) processes continue to evolve. These differences create both opportunities and challenges for Pharma and Medtech companies preparing evidence, developing global plans, and equipping local affiliates with the right materials to secure access.

In this episode, Louise Maddison (Senior Consultant – Global Pricing and Market Access, Petauri Evidence) interviewed four regional experts:

• For Argentina: Eleonora Aiello (CEO at Ceibo Health Consulting)
• For Brazil: Alessandra Calabró (Independent expert in market access and government affairs)
• For Colombia: María Fernanda Escobar (Principal Advisor, InnovaSalud)
• For Mexico: Fernando del Río (Partner at InnovaSalud, GP at XB Ventures)

Together, they unpack the access landscape in their countries, sharing experience‑based insight to help global teams refine evidence plans and align global materials to local payer expectations.

Together, they explore:

• Variation in healthcare systems, regulatory structures, and payer landscapes across LATAM
• HTA landscape in key markets and the influence of bodies such as CONITEC in Brazil, IETS in Colombia, CENETEC in Mexico, and ANEFiTS in Argentina
• Differences in evidence expectations, including clinical, economic, and real‑world data requirements
• How global dossiers, value messages, and evidence packages can better support affiliates engaging with local payers
• Opportunities and challenges for introducing Pharma and Medtech innovations into LATAM markets
• Future policy, regulatory, and reimbursement developments to monitor across the region

This episode was first broadcast as a live webinar on Thursday 19th March 2026. For more information about this webinar see: https://petauri.com/insights/latam-market-access-unlocked/

For support with market access strategy and global launch, please reach out to evidence@petauri.com.

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Send us Fan Mail

What does the evolving NHS landscape look like through the eyes of a Chief Pharmacist, and how are integrated care system (ICS) pharmacy teams responding?

In this Petauri Evidence NHS Whispers session, we put your questions to Yousaf Ahmad (Chief Pharmacist and Director of Medicines Optimisation, Frimley ICS), as he shares how he and his colleagues are responding to the changing NHS environment. From system pressures and financial constraints to prescribing priorities and service redesign, Yousaf explored how ICS pharmacy teams are adapting, and what this means for industry partners.

This episode was first broadcast as live webinar on: Friday 24th October 2025.

Learn more about this episode at https://petauri.com/insights/evolving-nhs-ics-chief-pharmacists-perspective/

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence